New perspectives: Glioma in adult patients

Silvani, Antonio

doi:10.1177/03008916231159716

Cited by 5 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glioblastoma (GBM) is the most common and aggressive type of primary brain tumor, with an annual incidence of 3.5 cases per 100,000 population [1]. Unfortunately, the prognosis for GBM patients has not changed significantly over the past decade, with a median overall survival (OS) ranging from 14.6 to 20.5 months and a five-year survival rate of only 5% [1,2]. The current standard of care includes surgery, radiotherapy, and chemotherapy with concomitant temozolomide (TMZ).…”

Section: Introductionmentioning

confidence: 99%

New Avenues and Major Achievements in Phytocompounds Research for Glioblastoma Therapy

Majchrzak-Celińska,

Studzińska-Sroka

2024

Molecules

View full text Add to dashboard Cite

Phytocompounds have been evaluated for their anti-glioblastoma actions for decades, with promising results from preclinical studies but only limited translation into clinics. Indeed, by targeting multiple signaling pathways deregulated in cancer, they often show high efficacy in the in vitro studies, but their poor bioavailability, low tumor accumulation, and rapid clearance compromise their efficacy in vivo. Here, we present the new avenues in phytocompound research for the improvement of glioblastoma therapy, including the ways to enhance the response to temozolomide using phytochemicals, the current focus on phytocompound-based immunotherapy, or the use of phytocompounds as photosensitizers in photodynamic therapy. Moreover, we present new, intensively evaluated approaches, such as chemical modifications of phytochemicals or encapsulation into numerous types of nanoformulations, to improve their bioavailability and delivery to the brain. Finally, we present the clinical trials evaluating the role of phytocompounds or phytocompound-derived drugs in glioblastoma therapy and the less studied phytocompounds or plant extracts that have only recently been found to possess promising anti-glioblastoma properties. Overall, recent advancements in phytocompound research are encouraging; however, only with more 3D glioblastoma models, in vivo studies, and clinical trials it is possible to upgrade the role of phytocompounds in glioblastoma treatment to a satisfactory level.

show abstract

Section: Introductionmentioning

confidence: 99%

New Avenues and Major Achievements in Phytocompounds Research for Glioblastoma Therapy

Majchrzak-Celińska,

Studzińska-Sroka

2024

Molecules

View full text Add to dashboard Cite

show abstract

The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma

Güven,

Taşpınar,

Denizler-Ebiri

et al. 2023

Med Oncol

View full text Add to dashboard Cite

A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma

Silvani,

Franceschi

2024

Tumori

Self Cite

View full text Add to dashboard Cite

Patients with cerebral neoplasms have waited many years for effective molecularly-targeted treatment.In the September issue of the New England Journal of Medicine, Mellinghoff IK et al. reported the results of the INDIGO trial, opening new horizons. 1 This study involved Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, in patients with isocitrate dehydrogenase (IDH)-mutated glioma. IDH is an enzyme that catalyses the oxidative decarboxylation of isocitrate and therefore plays a key role in the Krebs cycle.A heterozygous point mutation in IDH1 causing an arginine to histidine substitution at amino acid 132 (IDH1 R132H) is found in most IDH-mutant gliomas. 2 This gainof-function mutation disrupts the conversion of isocitrate to alpha-ketoglutarate (α-KG) and instead favours the production of large amounts of the 'oncometabolite' D-2hydroxyglutarate (D-2HG).The most common primary adult brain tumor diagnosed in patients under 50 is isocitrate dehydrogenase (IDH)mutant glioma.In the Cancer Registry of the United States (CBTRUS) dataset, for cases diagnosed in 2018, the overall ageadjusted incidence of IDH-mutant gliomas in the US was 0.70/100,000 persons. 3 IDH-mutant tumors accounted for approximately 12% of all gliomas diagnosed, with a very high frequency in IDH-mutant and codeleted 1p and 19q oligodendrogliomas, where it occurs in almost as much as 90% of cases regardless of grading, and in nonco-deleted IDH-mutant astrocytomas, where it affects approximately 35% of patients. Grade 4 glioblastomas

show abstract

New perspectives: Glioma in adult patients

Cited by 5 publications

References 38 publications

New Avenues and Major Achievements in Phytocompounds Research for Glioblastoma Therapy

New Avenues and Major Achievements in Phytocompounds Research for Glioblastoma Therapy

The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma

A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma

Contact Info

Product

Resources

About